Research That Led to the First Human Transplant in 1967 FORUM
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Surgical Advances in Heart and Lung Transplantation
Anesthesiology Clin N Am 22 (2004) 789–807 Surgical advances in heart and lung transplantation Eric E. Roselli, MD*, Nicholas G. Smedira, MD Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA The first heart transplants were performed in dogs by Alexis Carrel and Charles Guthrie in 1905, but it was not until the 1950s that attempts at human orthotopic heart transplant were reported. Several obstacles, including a clear definition of brain death, adequate organ preservation, control of rejection, and an easily reproducible method of implantation, slowed progress. Eventually, the first successful human to human orthotopic heart transplant was performed by Christian Barnard in South Africa in 1967 [1]. Poor healing of bronchial anastomoses hindered early progress in lung transplantation, first reported in 1963 [2]. The first successful transplant of heart and both lungs was accomplished at Stanford University School of Medicine (Stanford, CA) in 1981 [3]. The introduction of cyclosporine to immunosuppres- sion protocols, with lower doses of steroids, led to the first successful isolated lung transplant, performed at Toronto General Hospital in 1983 [4]. Since these early successes at thoracic transplantation, great progress has been made in the care of patients with end-stage heart and lung disease. Although only minor changes have occurred in surgical technique for heart and lung transplantation, the greatest changes have been in liberalizing donor criteria to expand the donor pool. This article focuses on more recent surgical advances in donor selection and management, procurement and implantation, and the impact these advances have had on patient outcome. -
Clinical Policy: Lung Transplantation Reference Number: CP.MP.57 Coding Implications Last Review Date: 05/20 Revision Log
Clinical Policy: Lung Transplantation Reference Number: CP.MP.57 Coding Implications Last Review Date: 05/20 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Medical necessity criteria for the review of lung transplantation requests. Policy/Criteria I. It is the policy of health plans affiliated with Centene Corporation® that lung transplant for members with chronic, end-stage lung disease who have failed maximal medical therapy is medically necessary when all of the following criteria are met: A. High (> 50%) risk of death from lung disease within 2 years if lung transplantation is not performed. B. High (> 80%) likelihood of surviving at least 90 days after lung transplantation. C. High (> 80%) likelihood of 5-year post-transplant survival from a general medical perspective provided that there is adequate graft function. D. Does not have ANY of the following absolute contraindications: 1. Malignancy, except for non-melanoma localized skin cancer that has been treated appropriately, low grade prostate cancer, a malignancy that has been completely resected, or a treated malignancy determined to have a small likelihood of recurrence and acceptable future risks; 2. Untreatable significant dysfunction of another major organ system unless combined organ transplantation can be performed; 3. Uncorrected atherosclerotic disease with suspected or confirmed end-organ ischemia or dysfunction and/or coronary artery disease not amenable to revascularization; 4. Acute medical instability, including, but not limited to, acute sepsis, acute viral respiratory infection, myocardial infarction, and liver failure; 5. Uncorrectable bleeding diathesis; 6. Chronic infection with highly virulent and/or resistant microbes that are poorly controlled pre-transplant; 7. -
Lung Transplantation with the OCS (Organ Care System)
Lung Transplantation with the OCSTM (Organ Care System) Lung System Bringing Breathing Lung Preservation to Transplant Patients A Guide for You and Your Family DRAFT ABOUT THIS BOOKLET This booklet was created for patients like you who have been diagnosed with end-stage lung failure and are candidates for a lung transplant. It contains information that will help you and your family learn about options available to you for a transplant. This booklet includes information on your lungs, how they function, and respiratory failure. In addition, you will learn about a new way to preserve lungs before transplantation, called breathing lung preservation. Your doctor is the best person to explain your treatment options and their risks and to help you decide which option is right for you. The booklet explains: • Breathing lung preservation with the OCS™ Lung System • How the OCS™ Lung System works • Who is eligible for the OCS™ Lung System • Lung transplant complications • How the lungs function • What is respiratory failure and the treatment options • What to expect during your treatment • Summary of clinical data for the OCS™ Lung System • Contact Information Please read this booklet carefully and share it with your family and caregivers. For your convenience, a glossary is provided in the front of this booklet. Terms in the text in bold italics are explained in the glossary. If you have questions about the OCS™ Lung System that are not answered in this booklet, please ask your physician. This booklet is intended for general information only. It is not intended to tell you everything you need to know about a lung transplant. -
Newsletteralumni News of the Newyork-Presbyterian Hospital/Columbia University Department of Surgery Volume 13, Number 1 Summer 2010
NEWSLETTERAlumni News of the NewYork-Presbyterian Hospital/Columbia University Department of Surgery Volume 13, Number 1 Summer 2010 CUMC 2007-2009 Transplant Activity Profile* Activity Kidney Liver Heart Lung Pancreas Baseline list at year start 694 274 174 136 24 Deceased donor transplant 123 124 93 57 11 Living donor transplant 138 17 — 0 — Transplant rate from list 33% 50% 51% 57% 35% Mortality rate while on list 9% 9% 9% 15% 0% New listings 411 217 144 68 23 Wait list at year finish 735 305 204 53 36 2007-June 2008 Percent 1-Year Survival No % No % No % No % No % Adult grafts 610 91 279 86 169 84 123 89 6 100 Adult patients 517 96 262 88 159 84 116 91 5 100 Pediatric grafts 13 100 38 86 51 91 3 100 0 — Pediatric patients 11 100 34 97 47 90 2 100 0 — Summary Data Total 2009 living donor transplants 155 (89% Kidney) Total 2009 deceased donor transplants 408 (30% Kidney, 30% Liver) 2007-June 2008 adult 1-year patient survival range 84% Heart to 100% Pancreas 2007-June 2008 pediatric 1-year patient survival range 90% Heart to 100% Kidney or lung *Health Resource and Service Administration’s Scientific Registry of Transplant Recipients (SRTR) Ed Note. The figure shows the US waiting list for whole organs which will only be partially fulfilled by some 8,000 deceased donors, along with 6,600 living donors, who will provide 28,000 to 29,000 organs in 2010. The Medical Center’s role in this process is summarized in the table, and the articles that follow my note expand on this incredible short fall and its potential solutions. -
Chronic Lung Allograft Dysfunction Post Lung Transplantation: a Review of Computed Tomography Quantitative Methods for Detection and Follow-Up
Journal of Clinical Medicine Review Chronic Lung Allograft Dysfunction Post Lung Transplantation: A Review of Computed Tomography Quantitative Methods for Detection and Follow-Up Trieu-Nghi Hoang-Thi 1,2,3 , Guillaume Chassagnon 1, Thong Hua-Huy 3, Veronique Boussaud 4, Anh-Tuan Dinh-Xuan 3 and Marie-Pierre Revel 1,* 1 AP-HP.Centre, Hôpital Cochin, Department of Radiology, Université de Paris, 75014 Paris, France; [email protected] (T.-N.H.-T.); [email protected] (G.C.) 2 Department of Diagnostic Imaging, Vinmec Central Park Hospital, Ho Chi Minh City 70000, Vietnam 3 AP-HP.Centre, Hôpital Cochin, Department of Respiratory Physiology, Université de Paris, 75014 Paris, France; [email protected] (T.H.-H.); [email protected] (A.-T.D.-X.) 4 AP-HP.Centre, Hôpital Cochin, Department of Pneumology, Université de Paris, 75014 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-1-5841-2471 Abstract: Chronic lung allograft dysfunction (CLAD) remains the leading cause of morbidity and mortality after lung transplantation. The term encompasses both obstructive and restrictive pheno- types, as well as mixed and undefined phenotypes. Imaging, in addition to pulmonary function tests, plays a major role in identifying the CLAD phenotype and is essential for follow-up after Citation: Hoang-Thi, T.-N.; lung transplantation. Quantitative imaging allows for the performing of reader-independent precise Chassagnon, G.; Hua-Huy, T.; Boussaud, V.; Dinh-Xuan, A.-T.; evaluation of CT examinations. In this review article, we will discuss the role of quantitative imaging Revel, M.-P. -
Historical Perspectives of Lung Transplantation: Connecting the Dots
4531 Review Article Historical perspectives of lung transplantation: connecting the dots Tanmay S. Panchabhai1, Udit Chaddha2, Kenneth R. McCurry3, Ross M. Bremner1, Atul C. Mehta4 1Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA; 2Department of Pulmonary and Critical Care Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA; 3Department of Cardiothoracic Surgery, Sydell and Arnold Miller Family Heart and Vascular Institute; 4Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA Contributions: (I) Conception and design: TS Panchabhai, AC Mehta; (II) Administrative support: TS Panchabhai, RM Bremner, AC Mehta; (III) Provision of study materials or patients: TS Panchabhai, U Chaddha; (IV) Collection and assembly of data: TS Panchabhai, U Chaddha, AC Mehta; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Atul C. Mehta, MD, FCCP. Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA; Staff Physician, Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. Email: [email protected]. Abstract: Lung transplantation is now a treatment option for many patients with end-stage lung disease. Now 55 years since the first human lung transplant, this is a good time to reflect upon the history of lung transplantation, to recognize major milestones in the field, and to learn from others’ unsuccessful transplant experiences. James Hardy was instrumental in developing experimental thoracic transplantation, performing the first human lung transplant in 1963. George Magovern and Adolph Yates carried out the second human lung transplant a few days later. -
HARBIN. NOVEMBER 2017. Sergio
POWER OVER LIFE AND DEATH Natalie Köhle ARBIN. NOVEMBER 2017. Sergio NESS is NOT in the BRAIN, which seeks HCanavero and Ren Xiaoping 任晓 to prove the existence of an eternal 平 announced that the world’s first hu- soul on the basis of near death experi- man head transplant was ‘imminent’. ence, as well as two guides on seducing They had just completed an eight- women. He also drops flippant refer- een-hour rehearsal on two human ca- ences to Stalin or the Nazi doctor Josef davers, and now claimed to be ready Mengele. for the real deal: the transplant of a human head from a living person with a degenerative disease onto a healthy, but brain-dead, donor body.1 Ren — a US-educated Chinese orthopaedic surgeon, was part of the team that performed the first hand transplant in Louisville in 1999. Canavero, an Italian, and former neu- rosurgeon at the university of Turin, is the more controversial, maverick per- sona of the team. In addition to many respected scientific publications, he Frankenstein’s Monster from The Bride of Frankenstein (1935) published Immortal: Why CONSCIOUS- Source: Commons Wikimedia 276 tor function and sensation. It would 277 also depend on the unproven capacity of the human brain to adjust to — and gain control over — a new body and a new nervous system without suffering debilitating pain or going mad.2 So far, Ren and Canavero have Sergio Canavero transplanted the heads of numerous Source: 诗凯 陆, Flickr lab mice and one monkey, and they Ren and Canavero see the head have also severed and subsequently Power over Life and Death Natalie Köhle transplant, formally known as cepha- mended the spinal cords of several POWER losomatic anastomosis, as the logical dogs. -
Islet Interleukin-1Β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to Β-Cell Failure
Diabetes Care 1 Islet Interleukin-1b Rebecca L. Hull,1 Ronald L. Gibson,2 Sharon McNamara,2 Gail H. Deutsch,3 Immunoreactivity Is an Early Corinne L. Fligner,3 Charles W. Frevert,1,4 Bonnie W. Ramsey,2 and Srinath Sanda5,6 Feature of Cystic Fibrosis That May Contribute to b-Cell Failure https://doi.org/10.2337/dc17-1387 OBJECTIVE Cystic fibrosis–related diabetes (CFRD) is a common complication of cystic fibrosis (CF), increasing patient morbidity and mortality. Poor understanding of CFRD path- ogenesis limits the development of targeted therapies to treat and/or prevent the disease. The aim of this study was to evaluate islet pathology, specifically, inflam- mation, amyloid deposition, and endocrine cell composition in subjects with CF with diabetes and with CF without diabetes. RESEARCH DESIGN AND METHODS A retrospective analysis of archived pancreas tissue collected at autopsy was con- ducted using pancreas tissue from subjects with CF and diabetes (CFRD) (n = 18) and PATHOPHYSIOLOGY/COMPLICATIONS CF without diabetes (CF-no DM) (n = 17). Two cohorts of control non-CF subjects were identified, each matched to CFRD and CF-no DM subjects for age, sex, and BMI (non-CF older, n = 20, and non-CF younger, n = 20), respectively. Immunohistochem- istry was performed to assess IL-1b and islet hormone (insulin, glucagon, somato- statin, and pancreatic polypeptide) immunoreactivity; histochemistry was performed 1Department of Medicine, University of Wash- to quantify amyloid deposition. ington, Seattle, WA 2Department of Pediatrics, University of Wash- RESULTS ington, Seattle, WA 3Department of Pathology, University of Wash- Islet IL-1b immunoreactivity was substantially increased in both CFRD and CF-no DM ington, Seattle, WA subjects compared with non-CF subjects and was common in young subjects with CF 4Department of Comparative Medicine, Univer- (£10 years of age). -
Lung Transplantation Adriaan Myburgh
Lung Transplantation Adriaan Myburgh ! UNIVERSITY OF CAPE TOWN ! Department of Anaesthesia and Perioperative Medicine ! ! ! ! ! ! ! Disclosure Jenna Lowe “ Get me to 21” • 4065 Donors Phalo - URE History • 1947: Vladimir Demikhov performs first successful animal lung transplantation • 1963: James Hardy performs first human lung transplantation in Jackson Mississippi 3 December 1967: First Human heart transplant Denise Darvall to Louis Washkansy • 1986: Joel Cooper performs first successful human double lung transplantation • 2001: Stig Steen performed first successful Non Heart Beating lung transplantation • 2007: Stig Steen performs first ex-vivo reconditioning human lung transplantation Recipients Relative contraindications to lung transplantation • Age > 65 years • Critical or unstable condition (eg, shock, ECMO) • Severely limited functional status • Colonization with highly resistant bacteria, fungi or mycobacteria • Severe obesity (BMI > 30 kg/m2) • Severe osteoporosis • Mechanical ventilation • Other significant medical conditions Orens JB et al. J Heart Lung Transplant 2006; 25: 745-55 Contraindications ? Relative contraindications to lung transplantation • Age > 65 years • Critical or unstable condition (eg, shock, ECMO) • Severely limited functional status • Colonization with highly resistant bacteria, fungi or mycobacteria • Severe obesity (BMI > 30 kg/m2) • Severe osteoporosis • Mechanical ventilation • Other significant medical conditions ECMO Bridge-to-transplant Lung assist device (Novalung®) ECMO Strueber M. Curr Opin Organ -
Hearts with Cardiac Arrest History Safe for Transplant in the Context Of
Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2015 Hearts With Cardiac Arrest History Safe For Transplant In The onC text Of Donor And Recipient Factors Aditi Balakrishna Yale School of Medicine, [email protected] Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Recommended Citation Balakrishna, Aditi, "Hearts With Cardiac Arrest History Safe For Transplant In The onC text Of Donor And Recipient Factors" (2015). Yale Medicine Thesis Digital Library. 1945. http://elischolar.library.yale.edu/ymtdl/1945 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. Hearts With Cardiac Arrest History Safe For Transplant in the Context Of Donor And Recipient Factors A Thesis Submitted to the Yale University School of Medicine in Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine by Aditi Balakrishna MD Candidate, Class of 2015 Yale School of Medicine Under the supervision of Dr. Pramod Bonde, Department of Surgery Abstract Background: Cardiac arrest, or downtime, can result in ischemic damage to myocardial tissue, which prompts caution in accepting hearts with such a history for transplant. Our aim is to provide guidance about whether these hearts are suitable and which among them confer optimal outcome. -
The Morality of Head Transplant: Frankenstein’S Allegory
5 THE MORALITY OF HEAD TRANSPLANT: FRANKENSTEIN’S ALLEGORY Aníbal Monasterio Astobiza1 Abstract: In 1970 Robert J. White (1926-2010) tried to transplant the head of a Rhesus monkey into another monkey’s body. He was in- spired by the work of a Russian scientist, Vladimir Demikhov (1916- 1998), who had conducted similar experiments in dogs. Both Demikhov and White have been successful pioneers of organ transplantation, but their scientific attempts to transplant heads of mammals are often remem- bered as infamous. Both scientists encountered important difficulties in such experiments, including their incapacity to link the spinal cord, which ended up by creating quadriplegic animals. In 2013, neurosurgeon Sergio Canavero claimed his capacity and plan to carry out the first human head 1 I am grateful to the Basque Government sponsorship for carrying out a posdoc- toral research fellowship at the Uehiro Centre for Practical Ethics of the University of Oxford, and to the latter institution for its warm welcome. Also, I would like to thank David Rodríguez-Arias for his invaluable comments and suggestions for the improvement of this paper. As usual, any error is solely the author’s responsibility. This work was carried out within the framework of the following research projects: KONTUZ!: “Responsabilidad causal de la comisión por omisión: Una dilucidadión ético-jurídica de los problemas de la acción indebida” (MINECO FFI2014-53926-R); “La constitución del sujeto en la interacción social: identidad, normas y sentido de la acción desde la perspectiva de la filosofía de la acción, la epistemología y la filosofía experimental” (FFI2015-67569-C2-2-P), and “Artificial Intelligence and Biotechnol- ogy of Moral Enhancement Ethical Aspects” (FFI2016-79000-P). -
Airway Versus Transbronchial Biopsy and BAL in Lung Transplant Recipients: Different but Complementary
Eur Respir J 1997; 10: 2876–2880 Copyright ERS Journals Ltd 1997 DOI: 10.1183/09031936.97.10122876 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Airway versus transbronchial biopsy and BAL in lung transplant recipients: different but complementary C. Ward, G.I. Snell, B. Orsida, L. Zheng, T.J. Williams, E.H. Walters Airway versus transbronchial biopsy and BAL in lung transplant recipients: different Dept of Respiratory Medicine, Alfred but complementary. C. Ward, G.I. Snell, B. Orsida, L. Zheng, T.J. Williams, E.H. Walters. Hospital and Monash University Medical ©ERS Journals Ltd 1997. School, Melbourne, Australia. ABSTRACT: Lung transplantation is now an established therapeutic intervention Correspondence: E.H Walters for end-stage cardiopulmonary disease in humans. Chronic rejection, in the form Dept of Respiratory Medicine of bronchiolitis obliterans syndrome (BOS), remains the commonest cause of mor- Alfred Hospital bidity and mortality in those surviving more than 3 months. The pathology of BOS Prahran involves airway changes. We have evaluated the potential for endobronchial biop- Melbourne sies (EBB) to complement existing sampling methods used in allograft monitoring Victoria 3181 and have compared the results of EBB findings with those of bronchoalveolar Australia lavage (BAL) and transbronchial biopsy (TBB) in 18 clinically stable patients. Keywords: Bronchoalveolar lavage We found that all the EBB had inflammatory cells present but that only five endobronchial biopsy TBB specimens had evidence of inflammation, with airway material being present lung transplant in 78% of the TBB. Paired BAL and EBB yielded different results, with no cor- transbronchial biopsy relations between total macrophages, lymphocytes, CD4+ cells or CD8+ cells.